Literature DB >> 7710956

Preoperative serum levels of CEA and CA 242 in colorectal cancer.

M Carpelan-Holmström1, C Haglund, P Kuusela, H Järvinen, P J Roberts.   

Abstract

Preoperative serum levels of CEA and CA 242 were determined in 260 patients with colorectal cancer and in 92 patients with benign colorectal diseases. The overall sensitivity of the CEA test was 43% and of the CA 242 test 39%. The corresponding specificities were 90% and 87% respectively, using 5 ng ml-1 as cut-off level for CEA and 20 U ml-1 for CA 242. The sensitivity of CEA was 26%, 32%, 38% and 77% for Dukes A, B, C and D colorectal cancer, and the sensitivity of CA 242 was 26%, 26%, 40% and 67%, respectively. The correlation between CEA and CA 242 was low. Concomitant elevation of both markers was seen in 5%, 12%, 18% and 59% of patients with Dukes A, B, C and D colorectal cancer, respectively. Of all the patients, 23% showed elevation of both the CEA and the CA 242 level, whereas CEA alone was elevated in 20% and CA 242 alone in 15% of the patients with colorectal cancer. Combined use of both markers raised the overall sensitivity from 43% to 58%, but reduced the specificity from 90% to 80%. The increase in sensitivity by combining the two markers was most marked in Dukes A, B and C colorectal cancer. Either or both of the markers were elevated in 46%, 46% and 60% of the patients respectively. The clinical value of combining CEA and CA 242 seems very promising and should be further investigated in prospective studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7710956      PMCID: PMC2033721          DOI: 10.1038/bjc.1995.167

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Basic principles of ROC analysis.

Authors:  C E Metz
Journal:  Semin Nucl Med       Date:  1978-10       Impact factor: 4.446

Review 2.  CEA directed second-look surgery for colon and rectal cancer.

Authors:  J Minton; A H Chevinsky
Journal:  Ann Chir Gynaecol       Date:  1989

3.  Laboratory: The Cultivation of Endameba Gingivalis (Gros) from the Human Mouth.

Authors:  C C Young; C A Kofoid; H G Johnstone
Journal:  Am J Public Health Nations Health       Date:  1929-05

4.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

5.  Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.

Authors:  C Haglund; P J Roberts; H Jalanko; P Kuusela
Journal:  Scand J Gastroenterol       Date:  1992       Impact factor: 2.423

6.  Tumour markers in colorectal cancer.

Authors:  P J Roberts
Journal:  Scand J Gastroenterol Suppl       Date:  1988

7.  Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.

Authors:  P Kuusela; C Haglund; P J Roberts
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

8.  The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer.

Authors:  N R Hall; P J Finan; B M Stephenson; D A Purves; E H Cooper
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

9.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

10.  CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.

Authors:  C Haglund; J Lundin; P Kuusela; P J Roberts
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

View more
  4 in total

1.  Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.

Authors:  Xue-Qin Yang; Chuang Chen; Chun-Wei Peng; Shao-Ping Liu; Yan Li
Journal:  Med Oncol       Date:  2011-05-07       Impact factor: 3.064

2.  IMMUNOBIOLOGICAL MONITORING OF VARIOUS GASTROINTESTINAL AND PRIMARY HEPATIC MALIGNANCIES.

Authors:  G S Chopra; K B Mishra; L S Vohra; M P Jaiprakash; J R Bhardwaj
Journal:  Med J Armed Forces India       Date:  2017-06-26

3.  Machine learning-featured Secretogranin V is a circulating diagnostic biomarker for pancreatic adenocarcinomas associated with adipopenia.

Authors:  Yunju Jo; Min-Kyung Yeo; Tam Dao; Jeongho Kwon; Hyon-Seung Yi; Dongryeol Ryu
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

4.  Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.

Authors:  M Carpelan-Holmström; C Haglund; J Lundin; H Alfthan; U H Stenman; P J Roberts
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.